41373-90-4

Usage

Uses

Used in Oncology:
4-PHENYL-3,6-PYRIDAZINEDIOL is used as an anticancer agent for its potential to selectively target and inhibit the growth of cancer cells. It is particularly effective in treating various types of cancer due to its ability to interfere with the enzymes that promote cell proliferation and survival in cancerous cells.
Used in Drug Development:
4-PHENYL-3,6-PYRIDAZINEDIOL is used as a drug candidate in the development of novel cancer therapies. Its high selectivity for cancer cells and low toxicity make it a valuable compound for further research and clinical trials to fully understand its therapeutic potential in cancer treatment.
Used in Pharmaceutical Research:
4-PHENYL-3,6-PYRIDAZINEDIOL is used as a subject of research in the pharmaceutical industry to explore its potential applications in cancer treatment. Further studies are needed to investigate its mechanism of action, efficacy, and safety in treating different types of cancer, as well as to develop optimal drug delivery systems for its administration.

InChI:InChI=1/C10H8N2O2/c13-9-6-8(10(14)12-11-9)7-4-2-1-3-5-7/h1-6H,(H,11,13)(H,12,14)

Upstream product

• 36122-35-7 2-phenylmaleic anhydride 
• 16110-98-8 (Z)-2-phenylbut-2-enedioic acid 
• 591-50-4 iodobenzene 

Downstream Products

• 93897-79-1 thiophosphoric acid O,O'-diethyl ester O''-(6-oxo-5-phenyl-1,6-dihydro-pyridazin-3-yl) ester 
• 92439-86-6 thiophosphoric acid O,O'-diethyl ester O''-(6-oxo-4-phenyl-1,6-dihydro-pyridazin-3-yl) ester 
• 41373-96-0 3,6-dichloro-4-phenyl-pyridazine 
• 92184-43-5 4-phenylpyridazine 
• 86663-07-2 4-Phenyl-3-chloropyridazine 
• 869487-49-0 6-chloro-5-phenyl-3-pyridazinylhydrazine 
• 54248-83-8 6-chloro-7-phenyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 54248-86-1 3-methyl-7-phenyl-[1,2,4]triazolo[4,3-b]pyridazine-6-ylchloride 
• 54248-88-3 3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine-6-ylchloride 

Relevant academic research and scientific papers

Pyridazinone derivative and application thereof

The invention provides a pyridazinone derivative and an application thereof, the pyridazinone derivative with the structure shown in the formula (I) provided by the invention has good activity as a thyroid hormone beta receptor agonist by selecting a specific modification group. The compound can be used for treating and/or preventing diseases caused by thyroid hormone regulation.

Facile Synthesis of New [1,2,4]Triazolo[4,3-b]pyridazine

A number of new [1,2,4]triazolo[4,3-b]pyridazines were prepared by either cyclocondesation of substituted hydrazinopyridazines with orthoesters or oxidative cyclization of their hydrazone analogs in nitrobenzene as an oxidizing agent. A host of other new

SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES

The invention relates to imidazo[1,2-b]pyridazines of general formula (I) a process for their manufacuture and their use for the treatment of benign and malignant neoplasia.

Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors

The design and synthesis of pyridazinone and phthalazinone derivatives are described. Newly synthesized compounds were tested on a panel of four kinases in order to evaluate their activity and potential selectivity. In addition, the promising compounds were tested on four cancer cell lines to examine cytotoxic effects. The compounds inhibited DYRK1A and GSK3 with different activity. SAR analysis and docking calculations were carried out to aid in the interpretation of the results. Taken together, our findings suggest that pyridazinone and phthalazinone scaffolds are interesting starting points for design of potent GSK3 and DYRK1A inhibitors.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Combination therapy

The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

QUANTITATIVE DETERMINATION OF THE ELECTRONIC EFFECTS OF 3- AND 4-PYRIDAZINYL GROUPS FROM NMR SPECTRAL DATA FOR ISOMERIC AMINOPHENYL- AND PHENYLPYRIDAZINES

The previously unknown aminophenylpyridazines were synthesized.The inductive and resonance constants of 3- and 4-pyridazinyl groups were calculated on the basis of 1H and 13C NMR spectral data for isomeric aminophenyl- and phenylpyridazines in dimethyl sulfoxide (DMSO).